This transaction
Acquisition of equity interest (making the company a wholly owned subsidiary)The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Supplies high-quality active pharmaceutical ingredients (APIs) and intermediates to major pharmaceutical companies and chemical companies in the European market
The impact on consolidated results for the fiscal year ending March 2027 is currently under review. The company will promptly disclose any matters requiring disclosure, including revisions to its earnings forecasts.
| Item | Details |
|---|---|
| Transaction name | Acquisition of equity interest (making the company a wholly owned subsidiary) |
| Name of the Subject Company | Framochem Francia-Magyar Finomkemiai Kft |
| Business Description of the Subject Company | Supplies high-quality active pharmaceutical ingredients (APIs) and intermediates to major pharmaceutical companies and chemical companies in the European market |
| Location of the Subject Company | Hungary |
| Date of Establishment of the Subject Company | 1993 (established) |
| Number of shares acquired | All equity interests (number of shares: Not disclosed) |
| Voting rights ownership percentage | After 100％ (before not disclosed) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review. The company will promptly disclose any matters requiring disclosure, including revisions to its earnings forecasts. |
| Contract Date | 27 March 2026 |
| Execution Date / Effective Date | 25 August 2026 (completed) |
| Conditions Precedent to Execution | Satisfaction of the conditions stipulated in the equity transfer agreement |
| Management structure after acquisition | Framochem became a wholly owned subsidiary (consolidated subsidiary) of 保土谷化学工業 and commenced operations under its new management structure. The Managing Director is Watanabe Noriyuki (渡辺 規之), an executive officer of the company, and the CEO of Framochem is Vörös Tamás. Employee terms and conditions: Not disclosed |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the specialty chemicals (phosgene derivatives) business within the Functional Resins segment, establish a Japan-Europe dual-hub structure by combining the European manufacturing base, technological capabilities and customer base with 保土谷化学工業's technological capabilities, and enhance competitiveness in global markets.